Search Results

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.

Foundery, a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced an initial closing of its inaugural fund, Foundery I, LP, with total capital commitments and contributed assets as of the closing equal to $29.6 million.

In this episode presented by Element Materials Technology, BioSpace’s head of insights discusses how China, historically focused on manufacturing, is increasingly becoming an innovation leader, particularly in pharmaceuticals, with guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney. Ultimately, balanced strategies involve domestic capacity investments coupled with global collaboration.